Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report

BACKGROUND: Conventional therapies for primary plasma cell leukemia (pPCL) are usually ineffective, with a short remission time with the use of multiple myeloma medications, showing aggressiveness of pPCL. B-cell lymphoma-2 inhibitor venetoclax is usually used for relapsed/refractory multiple myelom...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Fu, Li-Juan, Chen, Chun-Mei, Hu, Mei-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896656/
https://www.ncbi.nlm.nih.gov/pubmed/33644182
http://dx.doi.org/10.12998/wjcc.v9.i5.1175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896656/
https://www.ncbi.nlm.nih.gov/pubmed/33644182
http://dx.doi.org/10.12998/wjcc.v9.i5.1175

Ejemplares similares